Kenya Medical Device Renewal: Form 4 Dossier and Vigilance Reports

Content verified on: October 30, 2026

1. Key takeaways

• Renewal is applied for on Form 4 (regulation 9 of LN 100 of 2022); the renewal certificate is issued on Form 3 and is likewise valid for 5 years (regulation 10(1)).
• The hard precondition for acceptance is that the annual retention fees under regulation 8 have been paid in full and the re-registration and renewal guidelines have been observed; arrears in any single year constitute an obstacle to renewal.
• The renewal dossier comprises six categories: the product, non-clinical study reports, clinical study reports, changes, the quality review, and vigilance and product safety reports (including product complaints and market surveillance).
• The vigilance and product safety report is the largest documentary difference between renewal and first registration — first registration carries no historical vigilance data requirement, while renewal must submit one (regulation 9(3)(f)).
• Where a renewal application is made before expiry, the certificate remains valid until PPB makes its decision (regulation 10(2)); a late application falls outside that protection.

2. Legal basis

3. Expert insights

Insight 1: Cleared retention fees are an acceptance precondition, not a defect that can be cured later

Regulation 9 writes payment of the regulation 8 retention fees into the renewal filing as a precondition, not as a formal defect open to later correction. GRZAN notes the practical consequence: the renewal review will necessarily trace back across the payment record for the whole certificate cycle, so arrears in any one of the five years can surface all at once at renewal. This is exactly why retention receipts must be archived year by year — they are the evidence relied on at renewal, not just another invoice in the accounts payable folder.

Insight 2: The vigilance and product safety report turns five years of market performance into access evidence

Regulation 9(3)(f) requires the vigilance and product safety report and makes explicit that it covers product complaints and market surveillance data. This closes the loop with the post-market requirements and vigilance system in Article 7 of the Submission Document Guidelines: the manufacturer and the Local Authorized Representative (LAR) must keep distribution records, complaint handling procedures and records, adverse event reporting procedures and records, and must operate Field Safety Corrective Action (FSCA) procedures. GRZAN reads the core question of the renewal dossier as no longer what the product is but how the product has performed over these five years; the completeness and internal consistency of the vigilance data directly determine the outcome of the renewal.

Insight 3: The quality review and the change list together form the product’s five-year track record

Regulation 9 requires changes and the quality review to be submitted together. Taken jointly, they are a concentrated test of the licence holder’s change-management quality: whether every change was correctly classified into the four categories described in article 30, whether prior approval was obtained, and whether the label and the Declaration of Conformity were updated in step will all show up in the cross-check. GRZAN recommends organising the renewal dossier around the change ledger as its backbone rather than assembling documents at the last minute.

Insight 4: The boundaries of continuation-while-pending need active management

Regulation 10(2) provides protection in the form of continued validity pending a decision, triggered by an application filed before expiry. Because the current guideline text does not state a specific number of review days (any specific timeline is a practical estimate), GRZAN recommends submitting the renewal dossier at least 6 months before expiry and keeping the system acknowledgement after submission as proof that the application was indeed made before the certificate lapsed.

4. Practical recommendations

1. Start a year early. GRZAN recommends launching the renewal project 12 months before expiry, beginning with a check of payment records and the change ledger.
2. Check the payment record first. Compare retention fee receipts and system acknowledgements year by year; close any gap immediately and keep a written explanation.
3. Compile the vigilance data into a bound set. Summarise complaints, adverse events and market surveillance outcomes by year, keeping them consistent with the records required under Article 7.
4. Use the change ledger as the foundation. Organise the renewal dossier around the change notification ledger, annotating each entry with its classification, approval date and label synchronisation.
5. Keep the submission receipts. Save the system confirmation and email notices after renewal submission as evidence that the application was filed before expiry.
6. Re-check the approval pathway. If the approval status with the Reference Regulatory Agency (RRA) changed during the certificate period, re-assess the renewal pathway accordingly.

5. Verification checklist

• □ Has it been confirmed that renewal is applied for on Form 4 and the renewal certificate is issued on Form 3?
• □ Have the retention fees for every year of the certificate period been paid in full with receipts retained?
• □ Does the renewal dossier cover the six categories: product, non-clinical study reports, clinical study reports, changes, quality review, and vigilance and product safety reports?
• □ Does the vigilance and product safety report include product complaints and market surveillance data?
• □ Does the change ledger annotate each entry with its classification, prior approval and label synchronisation?
• □ Was renewal submitted at least 6 months before expiry with a system acknowledgement obtained?
• □ Have the conditions for continued validity during review under regulation 10(2) been confirmed?
• □ Have changes in RRA approval status during the certificate period been re-assessed and reflected in the renewal dossier?

Regulatory information verified as of October 30, 2026.

In African markets, the GRZAN regulatory team focuses on jurisdictions such as Kenya, Nigeria, South Africa and Egypt and runs a verification mechanism built on primary regulatory sources: every regulatory conclusion it publishes relies solely on official gazettes, the original texts of regulator guidelines and public legal databases, each marked with a verification date. Any figure, timeline or amount that cannot be located in an official source is flagged as a practical estimate rather than an assumption.

GRZAN services cover: market access strategy and risk-classification assessment; preparation and review of registration dossiers (CSDT, STED and CTD formats); selection and management of Local Authorized Representatives (LAR); quality management system and GMP/GSDP compliance coaching; post-market vigilance, change management and recall response; import customs clearance and PVoC coordination; regulatory intelligence subscriptions and corporate compliance ledgers.

For a Kenya market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.